<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585412</url>
  </required_header>
  <id_info>
    <org_study_id>YSP-RLH3001-01</org_study_id>
    <nct_id>NCT04585412</nct_id>
  </id_info>
  <brief_title>Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)</brief_title>
  <official_title>A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Palonosetron After Intravenous Administration of Palonosetron in Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yung Shin Pharm. Ind. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yung Shin Pharm. Ind. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two&#xD;
      formulations of palonosetron after intravenous administration of palonosetron in healthy&#xD;
      volunteers under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 24, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>An open-label, randomized, balanced, two-treatment, two-period, twosequence, single dose, two-way crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach peak concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUC0-∞)</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant (入z)</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of AUC0-t to AUC0-∞</measure>
    <time_frame>0 (pre-dose), ≤2, 5, 15, and 30 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours post dose</time_frame>
    <description>The two-sided 90% confidence interval for the difference of means in natural log-transformed Cmax, AUC0-t and AUC0-∞ between test and reference drug will be calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting, Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Palonosetron (Stothu®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stothu® Solution for Injection 0.25 mg/5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron (Aloxi®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aloxi® Solution for Injection 0.25 mg/5mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Pharmacokinetic study under fasting conditions</description>
    <arm_group_label>Palonosetron (Aloxi®)</arm_group_label>
    <arm_group_label>Palonosetron (Stothu®)</arm_group_label>
    <other_name>Stothu®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or female subjects between 20-45 years of age (inclusive) at the&#xD;
             screening visit.&#xD;
&#xD;
          2. Body mass index (BMI) between 18 and 27 kg/m2 (not inclusive) at the screening visit.&#xD;
&#xD;
          3. Acceptable medical history and physical examination including:&#xD;
&#xD;
               -  no particular clinically significant abnormalities in ECG results within six&#xD;
                  months prior to Period I dosing.&#xD;
&#xD;
               -  no particular clinical significance in general disease history within two months&#xD;
                  prior to Period I dosing.&#xD;
&#xD;
          4. Acceptable biochemistry determinations (within normal limits or considered by the&#xD;
             investigator or physician to be of no clinical significance) within two months prior&#xD;
             to Period I dosing, which includes AST (SGOT), ALT (SGPT), γ-GT, alkaline phosphatase,&#xD;
             total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol and&#xD;
             triglyceride (TG).&#xD;
&#xD;
          5. Acceptable hematology (within normal limits or considered by the investigator or&#xD;
             physician to be of no clinical significance) within two months prior to Period I&#xD;
             dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell&#xD;
             count with differentials and platelets.&#xD;
&#xD;
          6. Acceptable urinalysis (within normal limits or considered by the investigator or&#xD;
             physician to be of no clinical significance) within two months prior to Period I&#xD;
             dosing, which includes pH, blood, glucose, ketones, bilirubin and protein.&#xD;
&#xD;
          7. Female of childbearing potential practicing an acceptable method of birth control for&#xD;
             the duration of the study.&#xD;
&#xD;
          8. Have signed the written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A clinically significant disorder involving the cardiovascular, respiratory, hepatic,&#xD;
             renal, urinary tract, gastrointestinal, immunologic, hematologic, endocrine or&#xD;
             neurologic system(s) or psychiatric disease.&#xD;
&#xD;
          2. A clinically significant illness or surgery within four weeks prior to Period I&#xD;
             dosing.&#xD;
&#xD;
          3. History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder&#xD;
             disease, pancreas disorder over last two years or history of gastrointestinal tract&#xD;
             surgery over last five years.&#xD;
&#xD;
          4. History of kidney disease or urination problem over last two years deemed by the&#xD;
             investigator to be clinically significant.&#xD;
&#xD;
          5. Known or suspected history of drug abuse within lifetime.&#xD;
&#xD;
          6. History of alcohol addiction or abuse within last five years or use of more than 7&#xD;
             units of alcohol per week within two weeks prior to dosing. (1 unit of alcohol = 10 g&#xD;
             of alcohol or about 350 mL of beer or about 83 mL of red wine or about 30 mL of&#xD;
             beverage containing 40% (v/v) alcohol).&#xD;
&#xD;
          7. History of allergic response(s) to palonosetron or any other related drugs.&#xD;
&#xD;
          8. Evidence of chronic or acute infectious diseases.&#xD;
&#xD;
          9. Positive result for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody&#xD;
             (HCVAb), or human immunodeficiency virus (HIV).&#xD;
&#xD;
         10. Female subjects demonstrating a positive pregnancy screen prior to the study.&#xD;
&#xD;
         11. Female subjects who are currently breastfeeding.&#xD;
&#xD;
         12. Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks&#xD;
             prior to Period I dosing. Examples of inducers include: piperidines, carbamazepine,&#xD;
             dexamethasone and rifampin. Examples of inhibitors include: cimetidine,&#xD;
             diphenhydramine, fluvastatin, methadone and ranitidine.&#xD;
&#xD;
         13. Taking any prescription medications within four weeks or any nonprescription&#xD;
             medications (excluding flu vaccination) within two weeks prior to Period I dosing.&#xD;
&#xD;
         14. Use of any investigational drug within four weeks prior to Period I dosing.&#xD;
&#xD;
         15. Donating more than 250 mL of blood within two months prior to Period I dosing or&#xD;
             donating plasma (e.g. plasmapheresis) within two weeks prior to Period I dosing.&#xD;
&#xD;
         16. Any other medical reason as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

